To evaluate the safety and efficacy of Raptiva ® compared with placebo to control chronic
moderate to severe plaque psoriasis involving the hands and/or feet scoring Physician's
Global Assessment (PGA - H&F) greater-than or equal to 3 in subjects not suitable for other
systemic therapies including cyclosporine, methotrexate, and Psoralen-Ultraviolet Light A
(PUVA).